Treatments and compositions for attention deficit hyperactivity disorder: a patent review

References

• Garcia Rosales A, Vitoratou S, Banaschewski T, et al. Are all the 18 DSM-IV and DSM-5 criteria equally useful for diagnosing ADHD and predicting comorbid conduct problems? Eur Child Adolesc Psychiatry. 2015;24:1325–1337.
   PubMed Web of Science ®Google Scholar
• Connor DF, Ford JD. Comorbid symptom severity in attention-deficit/hyperactivity disorder: a clinical study. J Clin Psychiatry. 2012;73:711–717.
   PubMed Web of Science ®Google Scholar
• Nigg JT, Casey BJ. An integrative theory of attention-deficit/hyperactivity disorder based on the cognitive and affective neurosciences. Dev Psychopathol. 2005;17:785–806.
   PubMed Web of Science ®Google Scholar
• Cao M, Shu N, Cao Q, et al. Imaging functional and structural brain connectomics in attention-deficit/hyperactivity disorder. Mol Neurobiol. 2014;50:1111–1123.
   PubMed Web of Science ®Google Scholar
• Howard HR. Therapeutic agents for attention deficit disorders. Exp Opin Ther Patents. 2000;10:1549–1559.
   Web of Science ®Google Scholar
• Howard H. Agents for attention-deficit hyperactivity disorder - an update. Expert Opin Ther Patents. 2004;14:983–10008.
   Web of Science ®Google Scholar
• Eisenberg JM, Science CFCDaC. AHRQ Comparative Effectiveness ReviewsAttention Deficit Hyperactivity Disorder in Children and Adolescents. Comparative effectiveness review summary guides for clinicians. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012.
   Google Scholar
• Noven Pharmaceuticals. Composition and methos for transdermal delivery of amphetamine. WO2015100153. 2015.
   Google Scholar
• Gardner EL. Addiction and brain reward and antireward pathways. Adv Psychosom Med. 2011;30:22–60.
   PubMed Web of Science ®Google Scholar
• Childress AC, Sallee FR. Attention-deficit/hyperactivity disorder with inadequate response to stimulants: approaches to management. CNS Drugs. 2014;28:121–129.
   PubMed Web of Science ®Google Scholar
• Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology. 2008;33:1477–1502.
   PubMed Web of Science ®Google Scholar
• Lee M-S, Yang J-W, Ko Y-H, et al. Effects of methylphenidate and bupropion on DHEA-S and cortisol plasma levels in attention-deficit hyperactivity disorder. Child Psychiatry Hum Dev. 2008;39:201–209.
   PubMed Web of Science ®Google Scholar
• Cohen SC, Mulqueen JM, Ferracioli-Oda E, et al. Meta-analysis: risk of tics associated with psychostimulant use in randomized, placebo-controlled trials. J Am Acad Child Adolesc Psychiatry. 2015;54:728–736.
   PubMed Web of Science ®Google Scholar
• Rhine Pharmaceuticals. Compositions and methods for treating depression, ADHD and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations. WO2012118562. 2012.
   Google Scholar
• Popper CW. Pharmacologic alternatives to psychostimulants for the treatment of attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am. 2000;9:605–646.
   PubMed Web of Science ®Google Scholar
• Molina-Carballo A, Naranjo-Gomez A, Uberos J, et al. Methylphenidate effects on blood serotonin and melatonin levels may help to synchronise biological rhythms in children with ADHD. J Psychiat Res. 2013;47:377–383.
   PubMed Web of Science ®Google Scholar
• Shao L, Li W, Xie Q, et al. Triple reuptake inhibitors: a patent review (2006-2012). Expert Opin Ther Pat. 2014;24:131–154.
   PubMed Web of Science ®Google Scholar
• Prexa Pharmaceuticals. Multimediator transporter inhibitors for use in treatment of central nervous system disorders. WO2008024371. 2008.
   Google Scholar
• The Mclean Hospital Corporation. Methods for the treatment of ADHD and related disorders. WO2007100777. 2007.
   Google Scholar
• Neurovance. Use of (1r,5s)-(+)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters. WO2013019271. 2013.
   Google Scholar
• Patrick KS, Corbin TR, Murphy CE. Ethylphenidate as a selective dopaminergic agonist and methylphenidate-ethanol transesterification biomarker. J Pharm Sci. 2014;103:3834–3842.
   PubMed Web of Science ®Google Scholar
• Markowitz JS, Zhu H-J, Patrick KS. Isopropylphenidate: an ester homolog of methylphenidate with sustained and selective dopaminergic activity and reduced drug interaction liability. J Child Adolesc Psychopharmacol. 2013;23:648–654.
   PubMed Web of Science ®Google Scholar
• Musc Foundation for Research Development. Isopropylphenidate for the treatment of Attention-Deficit/Hyperactivity Disorder and fatigue-related disorders and conditions. WO2011011528. 2011.
   Google Scholar
• Shire. Abuse resistant lysine amphetamine compounds. WO2003034980. 2008.
   Google Scholar
• Jagotec AG Compositions comprising amphetamin and lisdexamfetamine. WO2011101374A1. 2012.
   Google Scholar
• Assistance Publique - Hopitaux De Paris. Mazindol combination in the treatment of Attention Deficit/Hyperactivity. WO2007116076. 2007.
   Google Scholar
• Aptalis Pharmatech. Orally disintegrating tablets of atomoxetine. WO2005105049. 2015.
   Google Scholar
• Vifor. Composition, useful for e.g. treating mental and behavioral disorders, comprises docosahexaenoic acid, eicosapentaenoic acid, gamma-linolenic acid, and psychostimulant comprising e.g. atomoxetine, and/or anxiolytic compound. WO2012049227. 2011.
   Google Scholar
• Lin DY, Kratochvil CJ, Xu W, et al. A randomized trial of edivoxetine in pediatric patients with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2014;24:190–200.
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Golembiowska K, Kowalska M, et al. Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder. Synapse. 2012;66:522–532.
   PubMed Web of Science ®Google Scholar
• Sunovion Pharmaceuticals Inc. Dosage of dasotraline and method for treatment of adhd. WO2015175523. 2015.
   Google Scholar
• Supernus Pharmaceuticals. Modified release formulations of viloxazine. WO201311979. 2013.
   Google Scholar
• Otsuka Pharmceuticals. New N,N-substituted 3-aminopyrrolidine compounds useful for treatment and/or prophylaxis of disorders caused by reduced neurotransmission of serotonin, norepinephrine or dopamine e.g. anxiety, hypertension and depression. WO2006121218. 2006.
   Google Scholar
• Lundbeck. 2-(1h-indolylsulfanyl) -aryl amine derivatives for use in the treatment of affective disorders, pain, ADHD and stress urinary incontinence. WO2006007843. 2005.
   Google Scholar
• Neurocure. Use of pharmaceutical compositions of lofepramine for the treatment of ADHD, CFS, FM and depression. WO2006038084. 2005.
   Google Scholar
• Adler LA, Gorny SW. Pilot study of Droxidopa with Carbidopa in adults with ADHD. J Atten Disord. 2015:1–10. DOI:10.1177/1087054715580393
   PubMed Web of Science ®Google Scholar
• Wigal SB, Duong S. Pharmacokinetic evaluation of eltoprazine. Expert Opin Drug Metab Toxicol. 2011;7:775–781.
   PubMed Web of Science ®Google Scholar
• Dhanoa DS. New deuterium-enriched pyridinonecarboxamide derivatives, useful for treating e.g. Alzheimer’s disease, cognitive impairment associated with schizophrenia, frontotemporal dementia, and attention deficit hyperactivity disorder. US2011021557. 2010.
   Google Scholar
• Langer SZ. α2-Adrenoceptors in the treatment of major neuropsychiatric disorders. Trends Pharmacol Sci. 2015;36:196–202.
   PubMed Web of Science ®Google Scholar
• Connor DF, Rubin J. Guanfacine extended release in the treatment of attention deficit hyperactivity disorder in children and adolescents. Drugs Today. 2010;46:299–314.
   PubMed Web of Science ®Google Scholar
• Ashare RL, Schmidt HD. Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal. Expert Opin Drug Discov. 2014;9:579–594.
   PubMed Web of Science ®Google Scholar
• Jing L, Li J-X. Trace amine-associated receptor 1: A promising target for the treatment of psychostimulant addiction. Eur J Pharmacol. 2015;761:345–352.
   PubMed Web of Science ®Google Scholar
• Hoffmann-La Roche. The use of benzamide derivatives for the treatment of CNS disorders. WO2009016088. 2009.
   Google Scholar
• Hoffmann-La Roche. Pyrazole carboxamide derivatives as taar modulators for use in the treatment of several disorders, such as depression, diabetes and parkinson’s disease. WO2014041007. 2014.
   Google Scholar
• Hoffman La Roche. Substituted-2-imidazoles. US7834044. 2010.
   Google Scholar
• Hoffmann-La Roche. Oxazoline derivatives for treatment of CNS disorders. WO2011057973. 2011.
   Google Scholar
• Fujimoto Co LTD. Prophylactic and therapeutic agent for attention-deficit/hyperactivity disorder. WO2015098591. 2015.
   Google Scholar
• Linton D, Barr AM, Honer WG, et al. Antipsychotic and psychostimulant drug combination therapy in attention deficit/hyperactivity and disruptive behavior disorders: a systematic review of efficacy and tolerability. Curr Psychiatry Rep. 2013;15:1–11.
   Web of Science ®Google Scholar
• Schreiber JE, Possin KL, Girard JM, et al. Executive function in children with attention deficit/hyperactivity disorder: the NIH EXAMINER battery. J Int Neuropsychol Soc. 2014;20:41–51.
   PubMed Web of Science ®Google Scholar
• Merz Pharmaceuticals. Sarizotan for use in the treatment of Attention Deficit Hyperactivity Disorder (ADHD). WO2012171653. 2012.
   Google Scholar
• Otsuka Pharmaceuticals. Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a CNS disorder. WO2012137971. 2012.
   Google Scholar
• Dainippon Sumitomo Pharma. Method of treatment for mental disorders. WO2012063513. 2012.
   Google Scholar
• Supernus Pharmaceuticals. Method of treatment of aggression. WO2014078394. 2014.
   Google Scholar
• Stocks JD, Taneja BK, Baroldi P, et al. A phase 2a randomized, parallel group, dose-ranging study of molindone in children with attention-deficit/hyperactivity disorder and persistent, serious conduct problems. J Child Adolesc Psychopharmacol. 2012;22:102–111.
   PubMed Web of Science ®Google Scholar
• Herrera-Guzman I, Herrera-Abarca JE, Gudayol-Ferre E, et al. Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on attention and executive functions in patients with major depressive disorder. Psychiatry Res. 2010;177:323–329.
   PubMed Web of Science ®Google Scholar
• Coughlin CG, Cohen SC, Mulqueen JM, et al. Meta-analysis: reduced risk of anxiety with psychostimulant treatment in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2015;25:611–617.
   PubMed Web of Science ®Google Scholar
• Pettersson M, Campbell BM, Dounay AB, et al. Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT(1A) partial agonists. Bioorg Med Chem Lett. 2011;21:865–868.
   PubMed Web of Science ®Google Scholar
• Howland RH. Brexpiprazole: another multipurpose antipsychotic drug? J Psychosoc Nurs Ment Health Serv. 2015;53:23–25.
   Web of Science ®Google Scholar
• Pfizer. Phenoxy-pyridyl derivatives. WO2009081259. 2009.
   Google Scholar
• Maccarrone M, Guzman M, Mackie K, et al. Programming of neural cells by (endo)cannabinoids: from physiological rules to emerging therapies. Nat Rev Neurosci. 2014;15:786–801.
   PubMed Web of Science ®Google Scholar
• Ariel - University Research and Development Company. CB2 receptor ligands for the treatment of psychiatric disorders. WO2014170902. 2014.
   Google Scholar
• Sanofi-Aventis. Treatment of diseases e.g. psychiatric disorder, obesity, pain, ulcer, bladder, urinary disorders asthma and osteoporosis, comprises administering N-methyl-N-trimethyl-cyclopenta-dienylmethyl-methane sulfonamide compound. US2008070962. 2008.
   Google Scholar
• Sanofi Aventis. New triazomethylamine derivatives, useful to treat/prevent psychotic, appetite, metabolic and gastro-intestinal disorders, inflammatory phenomena, immune system diseases, alcoholic/nicotinic dependency, are cannabinoid receptor antagonists. WO2007068814. 2007.
   Google Scholar
• Sanofi Aventis. New heterocyclic derivatives, useful to treat/prevent e.g. psychotic, appetite, metabolic and gastrointestinal disorders, inflammation, immune system disease and alcoholic/nicotinic dependency, are cannabinoid receptor antagonists. WO2007068815. 2005.
   Google Scholar
• Pharmorx Therapeutics. Treatments for depression and other diseases with a low dose agent. WO2014120936. 2014.
   Google Scholar
• Hoffmann La Roche. N-benzyl pyrrolidine derivatives. US8022099. 2011.
   Google Scholar
• Hoffmann La Roche. Pyrrolidine derivatives as dual nk1/nk3 receptor antagonists. WO2008128891. 2008.
   Google Scholar
• GSK. Pyridine derivatives and their use in the treatment of psychotic disorders. WO2007028654. 2007.
   Google Scholar
• Astrazeneca. A composition comprising (r)-spiro[l- azabicyclo[2.2.2]octane-3,2ʹ(3ʹh) -furo[2,3 -b]pyridine (azd0328) and its use in the treatment of Alzheimer’s disease, ADHD or cognitive dysfunction. WO2008115139. 2008.
   Google Scholar
• Potter AS, Dunbar G, Mazzulla E, et al. AZD3480, a novel nicotinic receptor agonist, for the treatment of attention-deficit/hyperactivity disorder in adults. Biol Psychiatry. 2014;75:207–214.
   PubMed Web of Science ®Google Scholar
• GSK. Novel lactam compounds. WO2011054773. 2011.
   Google Scholar
• Hoffman La Roche. Piperidine derivatives as nk3 receptor antagonists. WO2009033995. 2009.
   Google Scholar
• Merz Pharmaceuticals. Memantine for the treatment of childhood behavioral disorder. WO2006034465. 2005.
   Google Scholar
• Shim SH, Hwangbo Y, Yoon HJ, et al. Increased levels of plasma glial-derived neurotrophic factor in children with attention deficit hyperactivity disorder. Nord J Psychiatry. 2015;69:546–551.
   PubMed Web of Science ®Google Scholar
• The Board of Regents of The University of Texas System. Bivalent ampa receptor positive allosteric modulators. WO2013130501. 2013.
   Google Scholar
• Novartis. Quinazoline derivatives. US8299085. 2012.
   Google Scholar
• Sanofi Aventis. Use of new or known substituted 1H-quinazoline-2,4-dione compound to treat or prevent disorder related to the central nervous system and/or peripheral nervous system, preferably anxiety, insomnia, and Parkinson’s disease. WO2010109148. 2009.
   Google Scholar
• Tiligada E, Kyriakidis K, Chazot PL, et al. Histamine pharmacology and new CNS drug targets. CNS Neurosci Ther. 2011;17:620–628.
   PubMed Web of Science ®Google Scholar
• Glaxo. Treatment or prophylaxis of dementia, neurodegenerative disorders, schizophrenia, adhd, somnolence or epilepsy. WO2011051423. 2010.
   Google Scholar
• Arena Pharmaceuticals. Modulators of the histamine h3 receptor useful for the treatment of disorders related there to. WO2009105206. 2009.
   Google Scholar
• Sanofi Aventis. Novel fumarate salts of a histamine h3 receptor antagonist. WO2010151611. 2010.
   Google Scholar
• Ingenium Pharmaceuticals. New substituted pyrimidin-4-yl-aminophenyl-methanesulfonamide compound useful as cyclin-dependent kinase (CDK) inhibitor for treating e.g. pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases. WO2008129069. 2008.
   Google Scholar
• Merck. New aminoethane sulfonamide derivatives useful for treating e.g. sleep disorder, obesity, Alzheimer disease, cognitive impairment, depression, mania, hypertension, breast/prostate cancer, osteoarthritis and congestive heart failure, stroke. WO2007019234. 2006.
   Google Scholar
• Missbichler A, Gabor F, Reichl H Diaminooxidase-containing pharmaceutical compositions. WO2006003213. 2006.
   Google Scholar
• Dr Healthcare España. Diamine oxidase for use in the treatment or prevention of Attention Deficit Hyperactivity Disorder (ADHD). WO2013156955. 2013.
   Google Scholar
• Cellixbio Private. Compositions and methods for the treatment of neurological diseases and its associated complications. WO2014087367. 2014.
   Google Scholar
• Molina-Carballo A, Justicia-Martinez F, Moreno-Madrid F, et al. Differential responses of two related neurosteroids to methylphenidate based on ADHD subtype and the presence of depressive symptomatology. Psychopharmacology. 2014;231:3635–3645.
   PubMed Web of Science ®Google Scholar
• Alcobra Ltd. A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition. WO2010150261. 2010.
   Google Scholar
• Manor I, Rubin J, Daniely Y, et al. Attention benefits after a single dose of metadoxine extended release in adults with predominantly inattentive ADHD. Postgrad Med. 2014;126:7–16.
   PubMed Web of Science ®Google Scholar
• Minster Research. Use of sabcomeline for the treatment of ADD or ADHD. WO2010064047. 2010.
   Google Scholar
• Active. Method and pharmaceutical composition for treatment of mental disorders. WO2009147831. 2009.
   Google Scholar
• Abbott Laboratories. Sofinicline (abt-894) for attention-deficit/hyperactivity disorder. WO2009149003. 2011.
   Google Scholar
• Wilens TE, Gault LM, Childress A, et al. Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: results from two randomized placebo-controlled clinical trials. J Am Acad Child Adolesc Psychiatry. 2011;50:73–84.e1.
   PubMed Web of Science ®Google Scholar
• Potter AS, Schaubhut G, Shipman M. Targeting the nicotinic cholinergic system to treat attention-deficit/hyperactivity disorder: rationale and progress to date. CNS Drugs. 2014;28:1103–1113.
   PubMed Web of Science ®Google Scholar
• Martin CA, Nuzzo PA, Ranseen JD, et al. Lobeline effects on cognitive performance in ddult ADHD. J Atten Disord. 2013. doi:10.1177/1087054713497791.
   Google Scholar
• Pfizer Inc. Controlled-release dosage forms for varenicline. WO 2009034431. 2009.
   Google Scholar
• Genomind. Medical foods for the treatment of developmentally-based neuropsychiatric disorders via modulation of brain glycine and glutathione pathways. WO2012024293. 2011.
   Google Scholar
• Cellixbio Private. Compositions and methods for treatment of metabolic diseases. WO2014041446. 2014.
   Google Scholar
• Weisler RH, Pandina GJ, Daly EJ, et al. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. CNS Drugs. 2012;26:421–434.
   PubMed Web of Science ®Google Scholar
• Wallace TL, Ballard TM, Pouzet B, et al. Drug targets for cognitive enhancement in neuropsychiatric disorders. Pharmacol Biochem Behav. 2011;99:130–145.
   PubMed Web of Science ®Google Scholar
• Ilieva IP, Hook CJ, Farah MJ. Prescription stimulants’ effects on healthy inhibitory control, working memory, and episodic memory: a meta-analysis. J Cogn Neurosci. 2015;27:1069–1089.
   PubMed Web of Science ®Google Scholar
• Graf H, Abler B, Freudenmann R, et al. Neural correlates of error monitoring modulated by atomoxetine in healthy volunteers. Biol Psychiatry. 2011;69:890–897.
   PubMed Web of Science ®Google Scholar
• Chelonis JJ, Johnson TA, Ferguson SA, et al. Effect of methylphenidate on motivation in children with attention-deficit/hyperactivity disorder. Exp Clin Psychopharmacol. 2011;19:145–153.
   PubMed Web of Science ®Google Scholar